Dave Levitan

Five-year results of the randomized phase III ENESTnd trial show a positive risk-benefit profile for nilotinib in patients with CML, as compared to imatinib.

Some adult-onset cancer survivors have an increased risk of developing cardiovascular disease later in life compared to noncancer controls.

The 2012 change in guidelines regarding PSA testing for prostate cancer had a different effect on testing rates depending on which physician specialty was doing the testing.

The FDA has granted orphan drug designation for the novel agent known as TRC105, in development by Tracon Pharmaceuticals, for the treatment of soft-tissue sarcoma.

A novel prediction model can help predict long-term overall survival among breast cancer patients with distant metastases, according to a new study. The model could be used as a decision-making tool for physicians and patients.

The term “HER2-positive lung cancer” may actually refer to two distinct entities, according to a new study. HER2 mutations and HER2 amplifications were found in similar numbers of lung adenocarcinoma cases, but they did not occur in the same samples, suggesting HER2-targeted agents should differentiate between mutation and amplification.

Laboratory studies of mice and human cells found that a protein called Metastasis suppressor 1 (Mtss1) is downregulated in hematopoietic and progenitor cells when chronic myeloid leukemia is present. Mtss1 levels are restored when complete remission is achieved, suggesting the pathway might represent a new therapeutic target.

There was no significant difference in the decline in IQ score over time between pediatric brain tumor patients treated with either photon radiation or proton beam radiation therapy, according to a new study.

The US Food and Drug Administration announced the approval of eribulin (Halaven) for the treatment of unresectable, metastatic liposarcoma in patients who have received prior chemotherapy with an anthracycline.

Combined use of systematic and targeted magnetic resonance-ultrasound–guided fusion biopsy was effective in diagnosing clinically significant prostate cancer.

A study found that about half of advanced germ cell tumor patients with platinum-resistant or -refractory disease harbor potentially actionable mutations.

Breast cancer survivors with estrogen receptor (ER)-positive disease had a lower annual risk of recurrence within the first 5 years after diagnosis, though these patients then had higher rates than ER-negative patients after 5 years.

A pooled analysis revealed that the anticonvulsants valproic acid and levetiracetam do not improve progression-free or overall survival in patients with newly diagnosed glioblastoma.

A laboratory study found that the Hhex protein is overexpressed in acute myeloid leukemia cells and is necessary for their propagation but not for normal myelopoiesis.

Adult survivors of childhood astroglial tumors with significant vision loss are more likely to suffer various psychological and socioeconomic impacts such as unemployment.

Most adolescent and young adult survivors of Hodgkin lymphoma did not receive the recommended care within the first year post-treatment, according to a study.

A randomized trial showed that personalized care plans and one-on-one counseling can improve adherence to survivorship plans among low-income breast cancer survivors.

The FDA granted orphan drug designation for a developmental agent known as GPX-150, an analog of doxorubicin currently being tested for use in advanced or metastatic soft-tissue sarcoma.

An Egyptian study found that bladder cancer patients who underwent radical cystectomy had better local recurrence-free survival with adjuvant radiotherapy and chemotherapy combined, compared with chemotherapy alone.

A phase II trial of dasatinib found that the drug did not produce strong clinical benefit in most types of advanced sarcoma, though it may have activity in undifferentiated pleomorphic sarcoma.

Results from the large STAMPEDE trial suggest that the combination of zoledronic acid and celecoxib along with standard of care could improve failure-free survival in prostate cancer patients starting hormone therapy whose disease has metastasized.

The combination of the novel histone deacetylase inhibitor entinostat and high-dose interleukin-2 yielded a promising response rate in patients with metastatic renal cell carcinoma.

A three-arm trial found that one hypofractionation radiotherapy regimen was non-inferior to conventional RT for intermediate-risk prostate cancer patients.

A laboratory study showed that peroxisome proliferator-activated receptor gamma agonists such as pioglitazone could help treat chronic myeloid leukemia patients who are resistant or otherwise unresponsive to treatment with tyrosine kinase inhibitors.

A study of female cancer survivors found that almost half experience CIPN symptoms years after completing their cancer treatment.

The anti-PD-L1 antibody atezolizumab showed significantly improved objective response rates compared to historic controls in a phase II study of patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy.

A hypofractionated radiotherapy regimen was found to be noninferior to conventional fractionation for low-risk prostate cancer patients in a new randomized phase III trial.

An oncology pharmacist-managed program significantly increased adherence to tyrosine kinase inhibitor therapy among patients with chronic myeloid leukemia.

Patients diagnosed with HER2-amplified breast cancer at a younger age have a low risk of being a high-risk gene carrier, according to a new study examining susceptibility genes.

A meta-analysis found that radiotherapy for prostate cancer is associated with worse overall and prostate cancer–specific survival compared with surgery.